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Research
Although pharmaceuticals and pesticides are 
evaluated for toxicity at great cost, numer­
ous anthropogenic compounds produced in 
sizable amounts and present in our everyday 
environment have not been tested for any tox­
icologic activity. The recent California Green 
Chemistry Report (California Department of 
Toxic Substances Control 2008) illustrates 
that far more chemicals are in common use 
than the ones tested for toxicity, and in most 
cases, there are few or no toxicity data for a 
large number of these chemicals. Novel inter­
national legislation, such as the Registration, 
Evaluation, Authorization and Restriction of 
Chemicals (REACH) program implemented 
in 2007 by the European Union (European 
Chemicals Agency 2007), requires that all 
chemicals used in the European Union at 
more than 1 metric ton/year/company be 
evaluated for their toxicity over the next 
decade. Ultimately, the European Union may 
develop an authorization system to control 
substances of very high concern and pro­
gressively replace them with suitable alter­
natives where economically and technically 
viable, unless there is an overall benefit for 
society of using the substance. The U.S. 
Environmental Protection Agency has sev­
eral voluntary programs, including the High 
Production Volume Challenge Program (U.S. 
Environmental Protection Agency 1998), that 
allow compiling of chemical toxicity and haz­
ard information for selected chemicals. It is 
very likely that additional national and inter­
national legislation will be enacted that will 
require generation of toxicity data for most of 
the chemicals produced in sizable quantity.
For almost 200 years, laboratory animal 
testing has been the major tool of toxicologists 
(Gad 2006). However, such tests have the dis­
advantages of being both time­consuming and 
very costly because they require use of large 
number of animals, and they are not always 
predictive of human risk. For the implemen­
tation of REACH, Scialli (2008) estimated 
that tens of million of animals will be used 
at a cost of several hundred thousand dollars 
per compound, making it very challenging to 
use experimental animals to complete analy­
sis of the toxicologic effects of many chemi­
cals in a reasonable time frame. Accordingly, 
there is a need for accurate toxicologic eval­
uation of xenobiotics to be faster and more 
cost­effective. Progress in molecular biology, 
biotechnology, and other fields have paved 
the way for toxicity testing to be quicker, 
less expensive, and more directly relevant to 
human exposures (Gibb 2008). Although it is 
certain that in vitro assays cannot yet replace 
animal testing (Tingle and Helsby 2006), 
they may provide essential information that 
can prioritize and dramatically reduce the use 
of animal testing assays (Silliman and Wang 
2006). However, when considering the pros­
pect of screening tens of thousands of chemi­
cals against hundreds of in vitro assays, several 
important questions need to be answered. Can 
enzyme­ or cell­based bioassays yield useful 
toxicologic information? Furthermore, can 
these assays be conducted in a high­through­
put and reliable fashion, allowing the rapid 
screening of thousands of compounds for bio­
logical and toxicologic activities?
As part of the University of California–
Davis Superfund Basic Research Program, 
whose aim is to identify biomarkers of expo­
sure and effects of toxic substances, we have 
developed a library of techniques, including 
numerous enzyme­ and cell­based screening 
assays (Ahn et al. 2008; Garrison et al. 1996; 
Han et al. 2004; Huang et al. 2007; Jones et al. 
2005; Nagy et al. 2002; Rogers and Denison 
2000; Shan and Hammock 2001). Although 
such assays are routinely used to find novel 
small chemical inhibitors in the pharmaceuti­
cal industry, we tested whether such mecha­
nistically based screening assays can be used to 
rapidly provide information on the potential 
for compounds to produce specific biological 
toxic effects that would identify those requiring 
further in­depth study. More specifically, we 
tested whether these assays could be adapted 
for high­throughput screening (HTS). We 
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Ba c k g r o u n d: Legislation at state, federal, and international levels is requiring rapid evaluation of 
the toxicity of numerous chemicals. Whole-animal toxicologic studies cannot yield the necessary 
throughput in a cost-effective fashion, leading to a critical need for a faster and more cost-effective 
toxicologic evaluation of xenobiotics.
oBjectives: We tested whether mechanistically based screening assays can rapidly provide informa-
tion on the potential for compounds to affect key enzymes and receptor targets, thus identifying 
those compounds requiring further in-depth analysis.
Me t h o d s : A library of 176 synthetic chemicals was prepared and examined in a high-throughput 
screening (HTS) manner using nine enzyme-based and five receptor-based bioassays.
re s u l t s: All the assays have high Z´ values, indicating good discrimination among compounds in a 
reliable fashion, and thus are suitable for HTS assays. On average, three positive hits were obtained 
per assay. Although we identified compounds that were previously shown to inhibit a particular 
enzyme class or receptor, we surprisingly discovered that triclosan, a microbiocide present in per-
sonal care products, inhibits carboxylesterases and that dichlone, a fungicide, strongly inhibits the 
ryanodine receptors.
co n c l u s i o n s: Considering the need to rapidly screen tens of thousands of anthropogenic compounds, 
our study shows the feasibility of using combined HTS assays as a novel approach toward obtaining 
toxicologic data on numerous biological end points. The HTS assay approach is very useful to quickly 
identify potentially hazardous compounds and to prioritize them for further in-depth studies.
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selected a small (176 compounds) and structur­
ally very diverse library from among commonly 
encountered environmental chemicals. We 
report the results of screening this library with 
nine enzyme­based and five receptor­based bio­
assays. These assays were selected because the 
proteins involved were shown to interact with 
xenobiotics, and because the in vitro effects of 
these xenobiotics could be related to the in vivo 
activity of these proteins and health effects.
Materials and Methods
A more detailed account of the materials and 
methods used is given in the Supplemental 
Materials, (doi:10.1289/ehp.0900834.S1 via 
http://dx.doi.org/).
Chemicals. Most chemicals used in 
the library were from commercial sources. 
Chemicals were at least 95% pure and used 
without further purification.
Environmental chemicals library. The 
library was prepared in 2­mL deep­well poly­
propylene 96­well assay plates. Every com­
pound was dissolved at 10 mM in dimethyl 
sulfoxide (DMSO). Only compounds totally 
soluble at 10 mM in DMSO were included 
in the library. In each plate, the wells in the 
first column contained only DMSO to serve 
as controls. In the remainder of the plate, 
we dispensed one compound per well, with 
88 compounds total per plate. We created 
two plates for a total of 176 compounds. A 
detailed description of the chemical contents 
in each plate is presented in the Supplemental 
Materials, Tables 1 and 2 (doi:10.1289/
ehp.0900834.S1). The sealed plates were stored 
at –20°C until use. Upon use, the plates were 
diluted to the appropriate concentration using 
a robotic pipetting station.
Enzyme preparations. Recombinant 
human soluble epoxide hydrolase (sEH) was 
produced in a baculovirus expression system 
(Beetham et al. 1993) and purified by affin­
ity chromatography (Wixtrom et al. 1988). 
Recombinant human carboxylesterases CES1, 
CES2, and CES3; fatty acid amide hydrolase 
(FAAH); and paraoxonase 2 (PON2) were 
expressed in baculovirus­insect cells as previ­
ously described (Huang et al. 2007; Nishi et al. 
2006). The CESs were partially purified as pre­
viously described (Nishi et al. 2006), whereas 
microsomal preparations were used for FAAH 
and PON2 (Huang et al. 2007). Human liver 
cytosol and microsome extracts were obtained 
from BD Biosciences (San Jose, CA). Protein 
concentration was quantified using the Pierce 
BCA (bicinchoninic acid) assay (Pierce, 
Rockford, IL) using bovine serum albumin 
(BSA) as the calibrating standard.
Enzyme assays. Although the condi­
tions for each enzyme assay were different 
(for details, see Table 1), the enzymatic assays 
were all run in a similar format. Enzymes 
were used at a concentration that results in 
linear generation of product with increasing 
time and protein concentration, as well as 
yielding a signal that was 3–20 times greater 
than the background. BSA (0.1 mg/mL final 
concentration) was added to all buffers just 
before use to reduce nonspecific inhibition 
(McGovern et al. 2002). For glutathione 
S­transferase (GST) activities, the buffer was 
supplemented with 5 mM glutathione. For all 
the enzyme assays, we tested the compounds 
at final concentrations of 0.1 and 1 µM.
Kinetic assay conditions. The dissociation 
constant of triclosan for CES1 was determined 
following the method described by Dixon 
(1972) for competitive tight binding inhibi­
tors, using cyano(6­methoxy­2­  naphthyl)
methyl acetate (CMNA) as the substrate (Shan 
and Hammock 2001). Inhibitor concentra­
tions between 0 and 1,000 nM were incubated 
in triplicate for 5 min in sodium phosphate 
buffer (pH 7.4) at 30°C with 200 µL of the 
enzyme solution. Substrate at a final concen­
tration of 5–100 µM was then added. Velocity 
of the reaction was measured as described 
above. For each substrate concentration, plots 
of velocity as a function of inhibitor concen­
tration allow the determination of an appar­
ent inhibition constant (KIapp). The plot of 
KIapp as a function of the substrate concentra­
tion allows the determination of KI when the 
substrate concentration is zero. Results were 
expressed as the mean ± SD of three separate 
KI measurements.
Cell-based bioassays. Table 2 presents an 
overview of the different cell­based bioassays 
used. For all test compounds, agonist activ­
ity in the aryl hydrocarbon receptor (AhR), 
androgen receptor (AR), and estrogen recep­
tor (ER) assays was determined in the AhR, 
AR, and ER CALUX (chemically activated 
luciferase expression) bioassays, respectively. 
All three CALUX bioassays make use of differ­
ent cell lines (H1L6.1c2, T47D­AR–positive, 
and BG1Luc4E2/ER­α–positive, respectively) 
that contain a stably transfected luciferase 
gene under the transcriptional control of 
DNA response elements for the activated 
AhR, AR, and ER, respectively (Garrison et al. 
1996; Han et al. 2004; Rogers and Denison 
2000). Activation of the receptor signaling 
pathway was determined by quantifying the 
luciferase activity in the absence or presence 
of a known agonist [2,3,7,8­tetrachloro­
dibenzo­p­dioxin (TCDD), 17β­estradiol 
(E2), or dihydrotestosterone (DHT)]. Results 
were expressed relative to luciferase activity 
maximally induced by a reference compound 
(1 nM TCDD for AhR, 10 nM DHT for 
AR, 1 nM E2 for ER). For these assays, the 
primary screening of the library was done at 
10 µM. Membranes enriched in ryanodine 
receptors (RyRs) were obtained either from 
Table 1. Conditions for human enzyme-based bioassays.
Enzyme Preparation used Substrate
Concentration 
(µM) Buffer End point measured Reference
sEH Recombinant purified enzyme CMNPC 5 Bis-Tris/HCl pH 7.0, 25 mM Fluorescence kinetic Jones et al. 2005
CES1 Recombinant partially purified enzyme CMNA 50 Na2PO4 pH 7.4, 0.1 M Fluorescence kinetic Shan and Hammock 2001
CES2 Recombinant partially purified enzyme CMNA 50 Na2PO4 pH 7.4, 0.1 M Fluorescence kinetic Shan and Hammock 2001
CES3 Recombinant partially purified enzyme CMNA 50 Na2PO4 pH 7.4, 0.1 M Fluorescence kinetic Shan and Hammock 2001
FAAH Recombinant microsomes Octanoyl-MP 50 Na2PO4 pH 8.0, 0.1 M Fluorescence kinetic Huang et al. 2007
PON2 Recombinant microsomes CMNA 50 Na2PO4 pH 7.4, 0.1 M Fluorescence kinetic Shan and Hammock 2001
GSTs Pooled human liver cytosol CDNB 1,000 K2PO4 pH 6.5, 0.1 M Absorbance kinetic Habig et al. 1974
CYP450 1A2 and 2C6 Pooled human liver microsomes EROD 25 K2PO4 pH 7.4, 0.1 M Fluorescence kinetic Dutton et al. 1989
CYP450 2C9 Pooled human liver microsomes Luciferin H 50 K2PO4 pH 7.4, 0.1 M Luminescence Cali et al. 2006
Abbreviations: CDNB, 1-chloro-2,4-dinitrobenzene; CMNA, cyano(6-methoxy-2-naphthyl)methyl actetate; CMNPC, cyano(6-methoxy-naphthalen-2-yl)methyl trans-[3-phenyloxiran-2-yl)
methyl] carbonate; EROD, ethoxyresorufin; Octanoyl-MP, N-(6-methoxypyridin-3-yl) octanamide.
Table 2. Conditions for cell-based bioassays.
Human receptor Acronym Preparation used Substrate End point measured Reference
Aryl hydrocarbon receptor AhR Recombinant cells Luciferin Luminescence Han et al. 2004
Androgen receptor AR Recombinant cells Luciferin Luminescence Rogers and Denison 2000
Estrogen receptor ER Recombinant cells Luciferin Luminescence Rogers and Denison 2000
Ryanodine receptor 1 RyR1 Skeletal muscle membranes [3H]Ry Radioactivity Pessah et al. 1987
Ryanodine receptor 2 RyR2 Ventricular muscle membranes [3H]Ry Radioactivity Pessah et al. 1990High-throughput toxicology
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adult rabbit skeletal muscle, a pure type 1 
ryanodine receptor (RyR1) source (Saito et al. 
1984), or from cardiac ventri  cular tissue, a 
pure type 2 ryanodine receptor (RyR2) source 
(Pessah et al. 1990). Activation or inhibition 
of the receptors was measured by quantifying 
the ability of the tested compound at 5 µM to 
enhance or inhibit the basal binding of [3H]Ry 
(2 nM) in the presence of 20 µM CaCl2. After 
a 3­hr incubation at 37°C, the reactions were 
quenched by filtration through GF/B­grade 
glass fiber filters and washed twice with ice­
cold harvest buffer containing 20 µM CaCl2. 
[3H]Ry binding was quantified by measuring 
the radioactivity collected on the filter.
Selection of positive hits and counter-
screening. For the enzyme assays, a compound 
was selected as a positive hit if it resulted in 
> 50% inhibition at the lower concentration 
(100 nM) and if it resulted in more than 60% 
inhibition at the higher concentration (1 µM). 
For the cell­based assays, we selected com­
pounds that significantly (t­test and F­test, 
p < 0.01) induced the receptor activation of 
gene expression. For counterscreening, fresh 
solutions of all positive compounds were pre­
pared in DMSO. For the enzyme assays, the 
concentration of each compound that inhib­
ited 50% of the enzyme activity (IC50) was 
determined by measuring enzyme activities in 
the absence and presence of increasing con­
centrations of inhibitor (ranging from 0.5 to 
10,000 nM). IC50 values were calculated by 
nonlinear regression of at least five data points 
using SigmaPlot, version 9.01 (Systat Software 
Inc., Chicago, IL). Results are provided as the 
mean ± SD of at least three separate measure­
ments. Similarly, half­maximal effective con­
centration (EC50) values for agonists of the 
AhR and ER bioassays were determined, and 
the results are presented as the mean of tripli­
cate analysis. For the assay of [3H]Ry binding 
to RyR1 or RyR2, the influence of 5 µM of 
each compound was screened for its ability to 
either enhance or inhibit specific radioligand 
binding more than twice the baseline (defined 
as the level of [3H] Ry­specific binding in 
the presence of DMSO alone). Therefore, a 
positive hit on RyR1 or RyR2 was defined as 
≥ 200% of control binding for activators, or 
≤ 50% of control for inhibitors.
Results and Discussion
Assays characteristics and positive hits selec-
tion. Using results from the blank and full 
activity controls, we evaluated the suitability 
of each assay for use as HTS assays. We there­
fore calculated the signal­to­background ratio 
(S/B), the signal­to­noise ratio (S/N), and the 
Z´ factor as defined by Zhang et al. (1999). 
As shown in Table 3, we found that S/B ratios 
varied from 2.5 to > 150, with the lowest 
value for the absorbance­based assay (GSTs) 
and the highest for the radioactive­based 
assays (RyRs). Similarly, the S/N ratios varied 
greatly, with a lower value for the absorbance 
assay and the higher values for the radioactive­
based assays. In general, the enzyme­based 
assays yielded higher Z´ factors than did the 
cell­based bioassays. For the enzyme assays, 
Z´ values were > 0.7, indicating very good 
and reliable assays that are easily suitable for 
HTS assays. Although the cell­based assays 
yielded lower Z´ factors, the values were still 
> 0.5, suggesting that the discrimination is 
adequate and that these assays could be used 
in HTS assays. Nevertheless, for the RyR 
assays, a larger separation band and higher Z´ 
factor could be obtained by reducing the SD 
of the signal, which was around 20%.
The aims of the primary screening were to 
identify all possible positive hits and to ensure 
there were no false negatives. Thus, for the 
primary screening of the library, we tested the 
xenobiotics at relative high concentrations 
(0.1 and 1 µM for the enzymes, and 5 and 
10 µM for the receptors), which should be 
far higher than blood concentrations resulting 
from exposure. Thus, it is unlikely that com­
pounds found negative in the primary screen­
ing will be false negative and affect the tested 
proteins in vivo. Generally, testing higher con­
centrations result in solubility problems for an 
increasing proportion of compounds. Based 
on our definition of positive hits (described 
above), for the 14 assays we obtained a total 
of 69 positive results (Table 3), which rep­
resent on average five positive hits per assay, 
or 3% of the library. For FAAH, GST, and 
AR bioassays, we obtained no hits from the 
screening. There were twice as many posi­
tive hits from chemicals in plate II (42) than 
from those in plate I (27) [see Supplemental 
Material, Figure 1 (doi:10.1289/ehp.0900834.
S1)]. The latter plate contained numerous 
triazine herbicides that did not result in any 
significant inhibition in any assay. Although 
three compounds [carbophenothion, triclosan, 
and triphenyl phosphate (TPP)] gave positive 
results with three enzymes or more, all the 
target enzymes were esterases.
Even if the assays are of high quality, as 
defined by their S/B, S/N, and Z´ factors 
(described above), false positives are bound 
to happen as they are dependent on the com­
pounds tested and not on the assays. False pos­
itives are mostly due to nonspecific binding, 
alteration of the reporting signal (quenching 
of the fluorescence signal, cytotoxicity to the 
cells, etc.), and chemical modifications dur­
ing storage of the chemicals. The purpose of 
the counterscreening is to eliminate false posi­
tives. To reduce nonspecific inhibition, BSA 
(0.1 mg/mL final concentration) was added 
to all buffers just before use (McGovern et al. 
2002). To eliminate alteration of the report­
ing signal, we tested the ability of each positive 
hit to quench the fluorescent or luminescent 
signal as well as its possible cytotoxic effect. 
Unfortunately, it is not possible to run such 
controls in the primary screen format. Finally, 
to reduce false positives resulting from some 
chemical modification upon storage, we pre­
pared a fresh solution of each positive hit just 
before counterscreening. Out of the 69 positive 
hits initially found in the library screening, 
individual counterscreening analysis confirmed 
that 39 of them are effectively positive hits 
(see definition above), indicating an approxi­
mately 40% false­positive rate for the primary 
screening. This relatively high number of false 
positives reflects the high concentrations used 
for the primary screening. A lower screening 
concentration will have a lower number of 
false positives but will signi  ficantly increase the 
chance of false negatives, which is not desirable. 
Overall, using this two­step screening method, 
we found that 98% of the compounds tested 
have no effects on the tested assays.
Individual enzymes and receptors results. 
For all the positive hits selected from the library 
screening, we determined their individual 
Table 3. Characteristics and positive primary screen results for enzyme- and cell-based bioassays.
Assay characteristics No. of positive results
Assay S/Ba S/Na Z´a Primary screen Counterscreen
Enzyme
sEH 4.0 ± 0.1 38 ± 8 0.8 ± 0.1 2 2
CES1 11 ± 3 19 ± 2 0.8 ± 0.1 4 2
CES2 9.2 ± 0.9 106 ± 33 0.8 ± 0.1 4 3
CES3 6.1 ± 0.7 28 ± 7 0.7 ± 0.1 7 4
FAAH 150 ± 10 35 ± 5 0.8 ± 0.1 0 —
PON2 18 ± 2 134 ± 31 0.8 ± 0.04 4 3
GSTs 2.4 ± 0.5 28 ± 9 0.7 ± 0.05 0 —
CYP450 1A2 and 2C6 13 ± 5 48 ± 10 0.7 ± 0.1 1 0
CYP450 2C9 19 ± 4 79 ± 18 0.7 ± 0.05 12 7
Receptor
AhR 32 ± 1 410 ± 30 0.6 ± 0.2 3 2
AR 18 ± 2 180 ± 70 0.7 ± 0.1 0 —
ER 5 ± 1 80 ± 40 0.6 ± 0.1 8 5
RyR1 170 ± 30 500 ± 90 0.5 ± 0.1 12 8
RyR2 100 ± 10 310 ± 40 0.6 ± 0.1 12 4
aResults are mean ± SD of at least four independent measurements.Morisseau et al.
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inhibition or induction potency (IC50 or EC50) 
toward an enzyme or a receptor (Table 4), 
except for the RyR assays, which are the sub­
ject of a forthcoming study. As expected, 
we found that sEH was strongly inhibited 
by two urea­containing compounds, which 
are a well­  established class of sEH inhibitors 
(Morisseau et al. 1999): siduron and triclo­
carban [trichloro  carbanilide (TCC)]. Although 
siduron uses are limited, TCC is present in 
numerous personal care products (Ahn et al. 
2008), suggesting a large exposure risk. Animal 
models have shown that inhibition of the 
sEH affects human health by altering homeo­
stasis, blood pressure, inflammation, and pain 
(Morisseau and Hammock 2008).
Inhibition of the CESs by organo  phosphate 
xenobiotics (Table 4), such as carbo  phenothion, 
parathion, phosdrin, and TPP, was expected, 
because such compounds are common mech­
anistic suicide inhibitors of serine hydrolases 
after activation to the oxon form (Casida and 
Quistad 2005). Because the CESs are only 
slowly reactivated, there is thus a cumulative 
risk. Although many organophosphate insecti­
cides have been or are being phased out around 
the world, TPP continues to be used both as a 
plasticizer and a fire retardant in electronic com­
ponents. Burning or leaching of TPP from elec­
tronic waste could result in its presence in water 
(Owens et al. 2007). Given the role of CES in 
the metabolism of ester­ and amide­containing 
xenobiotics (Satoh and Hosokawa 2006), CES 
inhibition could lead to increased toxicity of 
xenobiotics. In general, CES inhibitors contain 
a carbonyl that reacts with the active­site serine 
to form a tetrahedral intermediate (Harada et al. 
2009). Thus, the inhibition of CES1 and CES2 
by triclosan, present in numerous personal care 
products (Ahn et al. 2008), was unexpected. 
To understand the mechanism of action of tri­
closan, we determined its kinetic constant [see 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.0900834.S1)]. We found that triclosan 
inhibits CES1 by a competitive mechanism and 
a KI of 105 ± 5 nM. Although not the most 
potent of known CES1 inhibitors, triclosan 
represents a lead compound for a new class of 
esterase inhibitors.
PON2 was first identified as an enzyme 
that protects humans from environmental 
poison  ing by organophosphate derivatives 
(James 2006); thus, one could expect apparent 
inhibition of this enzyme by organophosphates 
as we observed (Table 4). For carbophenothion 
and tributyl phosphotri  thioite, this is likely due 
to traces of oxon impurities. Interestingly, we 
found that, in addition to CES1 and CES2, 
TPP can also significantly reduce PON2 
activity. Inhibition of PON2 could lead to 
increased atherosclerosis and cardiovascular 
risk (James 2006). Taken together, exposure 
to TPP could affect human health through 
various modes of action.
For the two cytochrome P450 (CYP450) 
acti  vities tested, significant inhibition was 
observed only for CYP450 2C9 (Table 4). 
2­Methylheptyl­4,6­dinitrophenyl crotonate, 
the active ingredient in the fungicide dinocap, 
was the only very potent inhibitor of this 
CYP450 found. Interestingly CYP450 2C9 is 
involved in the production of antiinflamma­
tory and antihypertensive epoxyeicosatrienoic 
acids from arachidonic acid; thus, inhibition 
of this CYP450 could lead to increased cardio­
vascular risk (Morisseau and Hammock 2008).
Screening results for the three nuclear 
receptor signaling pathways (AhR, ER, and 
AR) identified seven compounds with sig­
nificant agonist activity: two for AhR, five 
for ER, and none for AR. Interestingly, even 
given the promiscuity of AhR ligand binding 
(Denison and Heath­Pagliuso 1998; Denison 
and Nagy 2003), only two fungicide chemi­
cals, 2­(4­chlorophenyl)­benzothiazole (CPB) 
and dichlone, induced AhR­dependent gene 
expression, and they were relatively weak 
inducers. CPB and dichlone EC50 values 
for induction (Table 4) were approximately 
5 × 105­fold less potent than the proto  typical 
AhR agonist TCDD. Although dichlone is a 
newly identified AhR agonist, CPB was pre­
viously reported to induce AhR­dependent 
expression of cytochrome CYP450 1A1 in 
human and mouse cell lines (Kärenlampi et al. 
1989). As expected, we found that ER sig­
nal transcription was activated by o,p´­DDT 
(dichlorodiphenyltrichloroethane) and its 
metabolites o,p´­DDE (dichlorodiphenyl­
dichloroethylene) and o,p´­DDD (dichloro­
diphenyldichloroethane) (Chen et al. 1997; 
Rogers and Denison 2000), and our screen­
ing identified o,p´­DDE and o,p´­DDD 
as activators also (o,p´­DDT was not pres­
ent in the screened library). In our system, 
the EC50 for induction by o,p´­DDE and 
o,p´­DDD was approximately 105­fold less 
potent than that of E2 (Rogers and Denison 
2000). Similarly, bisphenol A (BPA) and lin­
dane have also been previously identified as 
ER agonists (Bonefeld­Jørgensen et al. 2007; 
Maranghi et al. 2007; Steinmetz et al. 1996; 
Vandenberg et al. 2009), although lindane has 
been suggested to activate ER­dependent gene 
expression through a nonclassical mechanism 
(Steinmetz et al. 1996). BPA was the most 
potent ER agonist identified, only 3,000­fold 
less potent than E2, whereas lindane was the 
weakest. Taken together, the relatively low 
potency of these agonists coupled with exist­
ing controversies regarding exposure and 
health risks associated with BPA and other 
endocrine­disrupting chemicals (Vandenberg 
et al. 2009) suggests that the adverse effects of 
these chemicals remain to be determined.
Our primary screen revealed that numer­
ous compounds affected the RyRs, such as tri­
closan, which we previously showed to increase 
[3H]Ry binding to RyR1 (Ahn et al. 2008). 
For counterscreening, we concentrated on the 
12 chemicals that produced the most signifi­
cant RyR effect (Figure 1). Overall, the profiles 
Table 4. Positive counterscreen results for the enzyme assays and nuclear receptor–based bioassays.
Assay Compound IC50 or EC50 (nM)a Use
sEH Siduron 33 ± 3 Herbicide
TCC 13 ± 1 Microbiocide
CES1 Triclosan 210 ± 20 Microbiocide
TPP 43 ± 3 Flame retardant
CES2 Carbophenothion 34 ± 1 Insecticide
Triclosan 580 ± 30 Microbiocide
TPP 50 ± 2 Flame retardant
CES3 Carbophenothion 110 ± 15 Insecticide
Parathion 4.9 ± 0.4 Insecticide
Phosdrin 1.1 ± 0.1 Insecticide
Primiphos-ethyl 180 ± 20 Insecticide
PON2 Carbophenothion 110 ± 6 Insecticide
Tributyl phosphorotrithioite 120 ± 10 Herbicide
TPP 85 ± 8 Flame retardant
CYP450 2C9 2-Butan-2-yl-4,6-dinitro-phenol 1,900 ± 100 Pesticide
Chlorpyrifos 3,200 ± 200 Insecticide
Finasteride 1,500 ± 100 Antiandrogen
2-Methylheptyl-4,6-dinitrophenyl crotonate 120 ± 1 Fungicide
Pentachlorophenol 850 ± 10 Herbicide
Pyrethrum 2,300 ±100 Insecticide
Triclosan 650 ± 40 Microbiocide
AhR CPB 11,400 Fungicide
Dichlone > 10,000 Fungicide
ER BPA 330 Plastic monomer
o,p-DDD (dichlorodiphenyldichloroethane) 1,200 Insecticide
o,p-DDE (dichlorodiphenyldichloroethylene) 1,200 Insecticide
Endrin 13,000 Pesticide
Lindane > 50,000 Insecticide
aValues are IC50s for the enzyme-based assays (sEH to CYP450 2C9) and EC50s for the receptor-based assays (AhR and 
ER). Results are mean ± SD of at least three independent measurements.High-throughput toxicology
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for both receptors are similar, with the profile 
of RyR2 being more attenuated than that for 
RyR1. For the latter protein, we found eight 
compounds (at 5 µM) that significantly affected 
the binding of [3H]Ry: five of them inhibited 
the binding, and three increased it. For RyR2, 
we found four compounds that significantly 
inhibited this receptor. For both receptors, the 
largest effect was observed for chloranil (IC50 
< 1.0 µM) and dichlone (IC50 < 1.0 µM), 
which both contain in their structure a 2,3­di­
chloro­1,4­quinone. These results are consistent 
with our previously published work showing 
that naphthoquinones and benzoquinones are 
capable of selectively modifying RyR1 chan­
nels in a time­ and concentration­dependent 
manner (Feng et al. 1999). Interestingly, we 
found that [3H]Ry binding to RyR1 was 
increased almost 3­fold by chlorpyriphos and 
o,p´­DDE. Counterscreening results suggested 
that baythroid, α­cypermethrin, delta  methrin, 
and N­cyclohexyl­2­benzothiazyl sulfonamide 
have no significant effect on either RyR at 
5 µM. Obtaining a compound that interacts 
specifically with only one of the RyRs or has 
opposing effects on both proteins will be scien­
tifically very important. The deltamethrin scaf­
fold could be a lead toward such compounds, 
because deltamethrin seemed to have oppos­
ing effects on both RyRs. RyR1 and RyR2 
are major components of skeletal and cardiac 
muscle excitation contraction coupling, and 
several heritable mutations in these proteins 
have been associated with myogenic disor­
ders (Bellinger et al. 2008). In addition, RyR1 
and RyR2 are the major isoforms expressed 
in neurons and are responsible for producing 
temporally and spatially defined Ca2+ signals 
important for neuronal growth and plasticity 
(Berridge 2006). Deregulation of RyR func­
tion and expression contributes to alterations 
in activity­dependent dendritic growth and 
plasticity (Kenet et al. 2007; Roegge et al. 
2006; Yang et al. 2009) and the balance of 
excitatory and inhibitory neurotransmission 
in the hippocampus CA1 region (Kim et al. 
2009). Thus, exposure to the RyR channel 
activators and inhibitors identified here could 
trigger adverse contractile responses in muscle 
cells and affect proper brain development, 
especially in susceptible individuals.
Conclusion
The HTS method described herein allowed the 
elimination of 98% of the compounds as nega­
tive hits. Furthermore, we were able to cor­
rectly identify compounds that were previously 
shown to inhibit or induce a particular enzymes 
or receptor; however, we also discovered new 
effects of some xenobiotics. For example, the 
inhibition of CES1 and CES2 by triclosan 
was totally unexpected, as was the inhibition 
of the RyRs by chloranil and dichlone. These 
in vitro results raise significant biological/toxi­
cologic questions and further in vivo studies 
are necessary before drawing any conclusions 
on the health risks associated with any of these 
compounds by these specific mechanisms. 
Overall, our study shows the feasibility of using 
combined HTS assays as an approach toward 
obtaining toxicologic data on the many thou­
sands of anthropogenic compounds for which 
there is little if any information. Furthermore, 
the HTS assays were very useful for quickly 
identifying compounds of potential risk for 
further studies, thus concentrating resources on 
the potentially most significant chemicals.
The National Library of Medicine has 
developed the infrastructure to screen com­
pounds on possible pharmacologic leads 
and to report the data in an easily acces­
sible publically available format; this is 
part of the National Institutes of Health 
Molecular Libraries Roadmap initiative. The 
results for the screening of sEH in this sys­
tem are available online (National Center for 
Biotechnology Information 2009); the AhR 
CALUX bioassay is currently used in the same 
program. One useful rapid approach would 
be for investigators or the National Institute 
of Environmental Health Sciences to propose 
toxicologically relevant assays and also pro­
vide environmentally or industrially important 
compounds to the system.
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